Emama Arshad Abbasi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Emama Arshad Abbasi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Amna Akbar
Emergency and Accident, District Headquarter Hospital, Muzaffarabad, PAK
2 shared publications - Nisha Hamid Awana2 shared publications
- Sabahat Tasneem
Health Services Academy, Islamabad, Pakistan
2 shared publications - Sarosh Khan Jadoon
Combined Military Hospital/SKBZ, Muzaffarabad, AJK, Pakistan
2 shared publications - Soffia Khursheed
Histopathology Pakistan Institute of Medical Science Islamabad Pakistan
2 shared publications - Jahanzeb Ahmed
Trainee General Surgery Department of Gastrointestinal Surgery Second Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang
1 shared publication
Latest Publications
- Open Access
- 11 November 2023
- Published by Green Publication
- Vol. 30 (18) , 2048-2059
IMMUNOLOGICAL BIOMARKERS AND PROGNOSIS OF ENDOMETRIAL CANCER: A META-ANALYSIS
Objective: This research is to explore the relationship in immune related biomarkers and prognosis in endometrial cancer (EC). Method: This article searched relevant databases and literature, and ultimately included 13 articles for meta-analysis. During the literature screening process, irrelevant literature, as well as literature published in comments and academic conferences were excluded. Among the included literature, there are 6 articles related to miR-421 and 7 articles related to miR-548ag. The data processing of Meta-analysis adopts statistical methods. Result: The combined specificity and SROC curve results of meta-analysis showed that miR-421 and miR-548ag possess high diagnostic value for EC. At the same time, sensitivity analysis was conducted on the overall survival rate of OS, and no significant impact was found on combined HR and 95% CI in any study. This indicates that miR-421 and miR-548a possess an essential influence on the prognosis of EC and demonstrates the reliability of this analysis. Conclusion: The relevant outcomes suggest that miR-421 and miR-548ag may be biomarkers for the prognosis of endometrial cancer. These findings have important guiding significance for a deeper understanding of the pathogenesis, pathological and physiological changes, and clinical treatment of endometrial cancer. It is essential to conduct more research for validating the role of these biomarkers in the prognosis of endometrial cancer.
- 11 November 2023
- Published by Green Publication
- Vol. 30 (18) , 2048-2059
Open AccessIMMUNOLOGICAL BIOMARKERS AND PROGNOSIS OF ENDOMETRIAL CANCER: A META-ANALYSIS
Objective: This research is to explore the relationship in immune related biomarkers and prognosis in endometrial cancer (EC). Method: This article searched relevant databases and literature, and ultimately included 13 articles for meta-analysis. During the literature screening process, irrelevant literature, as well as literature published in comments and academic conferences were excluded. Among the included literature, there are 6 articles related to miR-421 and 7 articles related to miR-548ag. The data processing of Meta-analysis adopts statistical methods. Result: The combined specificity and SROC curve results of meta-analysis showed that miR-421 and miR-548ag possess high diagnostic value for EC. At the same time, sensitivity analysis was conducted on the overall survival rate of OS, and no significant impact was found on combined HR and 95% CI in any study. This indicates that miR-421 and miR-548a possess an essential influence on the prognosis of EC and demonstrates the reliability of this analysis. Conclusion: The relevant outcomes suggest that miR-421 and miR-548ag may be biomarkers for the prognosis of endometrial cancer. These findings have important guiding significance for a deeper understanding of the pathogenesis, pathological and physiological changes, and clinical treatment of endometrial cancer. It is essential to conduct more research for validating the role of these biomarkers in the prognosis of endometrial cancer.
- Open Access
- 11 November 2023
- Published by Green Publication
- Vol. 30 (18) , 2017-2028
ESOPHAGEAL MANOMETRY COMBINED WITH PROTON PUMP INHIBITOR TEST APPLIED IN THE DIAGNOSIS OF NON-CARDIAC CHEST PAIN ASSOCIATED WITH GASTRO-ESOPHAGEAL REFLUX DISEASE.
Background: Esophageal manometry (EM) and proton pump inhibitor (PPI) tests are used to see how well they could diagnose GERD-related chest pain that are not caused by the heart diseases. Methods: Randomly, 21cases of GERD-related NCCP and 8cases of non-GERD-related NCCP were assigned into two groups of total 29patients with NCCP. General information, esophageal dynamic indices, and the diagnostic effectiveness of PPI in patients from various groups were observed and documented. Results: The lower esophageal sphincter (LES)pressure at rest was found to be significantly lower in patients with non-cardiac chest pain (NCCP) caused by GERD than in patients with NCCP not caused by GERD. The mean LES resting pressure and mean residual pressure were also lower in the GERD-related NCCP group. Additionally, the maximum residual pressure was lower in the GERD-related NCCP group. These differences between the two groups were statistically significant, with a p-value less than 0.05. The PPI test yielded a sensitivity of 78.95%, a specificity of 83.33%, a positive predictive value (PPV) of 93.75%, and a negative predictive value (NPV) of 55.56% in relation to non-cardiac chest pain (NCCP) associated with gastro esophageal reflux disease (GERD). Conclusion: In summary, the utilization of high-resolution esophageal manometry (EM) has demonstrated significant diagnostic utility in the context of non-cardiac chest pain (NCCP). The strategic use of antispasmodic medications has the potential to alleviate symptoms experienced by individuals with non-cardiac chest pain (NCCP) and enhance their overall quality of life (QOL). Also, the proton pump inhibitor (PPI) test is widely thought to be the best way to diagnose non-cardiac chest pain (NCCP) caused by gastro-esophageal reflux disease (GERD) in a clinical setting.
- 11 November 2023
- Published by Green Publication
- Vol. 30 (18) , 2017-2028
Open AccessESOPHAGEAL MANOMETRY COMBINED WITH PROTON PUMP INHIBITOR TEST APPLIED IN THE DIAGNOSIS OF NON-CARDIAC CHEST PAIN ASSOCIATED WITH GASTRO-ESOPHAGEAL REFLUX DISEASE.
Background: Esophageal manometry (EM) and proton pump inhibitor (PPI) tests are used to see how well they could diagnose GERD-related chest pain that are not caused by the heart diseases. Methods: Randomly, 21cases of GERD-related NCCP and 8cases of non-GERD-related NCCP were assigned into two groups of total 29patients with NCCP. General information, esophageal dynamic indices, and the diagnostic effectiveness of PPI in patients from various groups were observed and documented. Results: The lower esophageal sphincter (LES)pressure at rest was found to be significantly lower in patients with non-cardiac chest pain (NCCP) caused by GERD than in patients with NCCP not caused by GERD. The mean LES resting pressure and mean residual pressure were also lower in the GERD-related NCCP group. Additionally, the maximum residual pressure was lower in the GERD-related NCCP group. These differences between the two groups were statistically significant, with a p-value less than 0.05. The PPI test yielded a sensitivity of 78.95%, a specificity of 83.33%, a positive predictive value (PPV) of 93.75%, and a negative predictive value (NPV) of 55.56% in relation to non-cardiac chest pain (NCCP) associated with gastro esophageal reflux disease (GERD). Conclusion: In summary, the utilization of high-resolution esophageal manometry (EM) has demonstrated significant diagnostic utility in the context of non-cardiac chest pain (NCCP). The strategic use of antispasmodic medications has the potential to alleviate symptoms experienced by individuals with non-cardiac chest pain (NCCP) and enhance their overall quality of life (QOL). Also, the proton pump inhibitor (PPI) test is widely thought to be the best way to diagnose non-cardiac chest pain (NCCP) caused by gastro-esophageal reflux disease (GERD) in a clinical setting.